Thumb Arthritis Market Highlights

Within orthopedic care, the Thumb Arthritis Market focuses on addressing arthritis specifically affecting the thumb joint, particularly the carpometacarpal joint. Arthritis in the thumb joint, also referred to as arthritis in the carpometacarpal joint of the thumb, is a progressive condition characterized by inflammation, pain, and stiffness in the base of the thumb. This degenerative condition can significantly impair hand function and diminish quality of life for affected individuals. The Thumb Arthritis Market provides a range of treatment options aimed at managing symptoms and preserving thumb function. Non-surgical interventions such as splinting, medication, and hand therapy may be recommended to alleviate pain and improve thumb mobility. In cases where conservative measures are insufficient, surgical interventions such as joint fusion or joint replacement may be considered to restore thumb function and alleviate symptoms. With ongoing advancements in orthopedic technology and increasing awareness of thumb arthritis, the Thumb Arthritis Market continues to evolve, offering tailored solutions to improve the lives of individuals affected by this condition.

The Thumb Arthritis Market insights report has estimated at USD 0.4 billion in 2022. Thumb arthritis market revenue is anticipated to increase from USD 0.43 billion in 2023 to USD 0.833 billion by 2032, growing at a compound yearly growth rate (CAGR) of 8.50% over the forecast period (2023-2032).

Segmentation

The global thumb arthritis market is segmented on the basis of type, diagnosis, treatment, and end user. On the basis of the type, the market is segmented into osteoarthritis thumb arthritis, rheumatoid thumb arthritis, and others. On the basis of the diagnosis, the market is segmented into physical examinations, imaging, fine needle aspiration (FNA), and others. The imaging segment is sub-segmented into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.

On the basis of the treatment, the market is segmented into thumb exercise, medication, surgery, and others. The medication segment is sub-segmented into OCT medications, prescription medications, and others. The surgery segment is sub-segmented into trapeziectomy, osteotomy, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, retail pharmacies, and others.

Regional Analysis

The Americas dominate the global thumb arthritis market. A well-developed healthcare sector, growing geriatric population, and increasing healthcare expenditure are the major drivers for the growth of the global thumb arthritis market.

Europe holds the second largest thumb arthritis market owing to the availability of the funds for research, increasing surgery adoption rates, and growing patient population.

Asia Pacific is the fastest growing region. Growing geriatric and obese population followed by the developing healthcare sector are boosting the market growth. Within the region, Australia holds a significant ratio of the obese population. However, the presence of the developing economies like India and China are marked by expanding healthcare sector. This is estimated to provide favorable backgrounds for the market growth.

The Middle East and Africa region account for the least market share. This is mainly due to the presence of the poor African economies within the region, which have low per capita income and lack of the medical services. On the other, the Middle East holds the largest market share within the region.

Key Players

The key players listed in the Thumb Arthritis Market outlook report are inclusive of BioPro (U.S.), McKie Splints (U.S.), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Carestream Health. (U.S.), General Electric Company (U.K), and others.

For more information visit at MarketResearchFuture